Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies

Michihiro Kobayashi, Sisi Chen, Rui Gao, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The phosphatases of regenerating liver (PRLs), consisting PRL1, PRL2 and PRL3, are dual-specificity protein phosphatases that have been implicated as biomarkers and therapeutic targets in several solid tumors. However, their roles in hematological malignancies are largely unknown. Recent findings demonstrate that PRL2 is important for hematopoietic stem cell self-renewal and proliferation. In addition, both PRL2 and PRL3 are highly expressed in some hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Moreover, PRL deficiency impairs the proliferation and survival of leukemia cells through regulating oncogenic signaling pathways. While PRLs are potential novel therapeutic targets in hematological malignancies, their exact biological function and cellular substrates remain unclear. This review will discuss how PRLs regulate hematopoietic stem cell behavior, what signaling pathways are regulated by PRLs, and how to target PRLs in hematological malignancies. An improved understanding of how PRLs function and how they are regulated may facilitate the development of PRL inhibitors that are effective in cancer treatment.

Original languageEnglish (US)
Pages (from-to)2827-2835
Number of pages9
JournalCell Cycle
Volume13
Issue number18
DOIs
StatePublished - 2014

Fingerprint

Hematologic Neoplasms
Hematopoietic Stem Cells
Phosphoric Monoester Hydrolases
Liver
Dual-Specificity Phosphatases
Phosphoprotein Phosphatases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Neoplasms
Cell Survival
Leukemia
Biomarkers
Therapeutics

Keywords

  • hematological malignancy and therapeutic target
  • hematopoietic stem cell
  • oncogenic signaling
  • PRL
  • PTP4A
  • self-renewal

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. / Kobayashi, Michihiro; Chen, Sisi; Gao, Rui; Bai, Yunpeng; Zhang, Zhong-Yin; Liu, Yan.

In: Cell Cycle, Vol. 13, No. 18, 2014, p. 2827-2835.

Research output: Contribution to journalArticle

Kobayashi, Michihiro ; Chen, Sisi ; Gao, Rui ; Bai, Yunpeng ; Zhang, Zhong-Yin ; Liu, Yan. / Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. In: Cell Cycle. 2014 ; Vol. 13, No. 18. pp. 2827-2835.
@article{30a71c28c0444df591102c1619573f74,
title = "Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies",
abstract = "The phosphatases of regenerating liver (PRLs), consisting PRL1, PRL2 and PRL3, are dual-specificity protein phosphatases that have been implicated as biomarkers and therapeutic targets in several solid tumors. However, their roles in hematological malignancies are largely unknown. Recent findings demonstrate that PRL2 is important for hematopoietic stem cell self-renewal and proliferation. In addition, both PRL2 and PRL3 are highly expressed in some hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Moreover, PRL deficiency impairs the proliferation and survival of leukemia cells through regulating oncogenic signaling pathways. While PRLs are potential novel therapeutic targets in hematological malignancies, their exact biological function and cellular substrates remain unclear. This review will discuss how PRLs regulate hematopoietic stem cell behavior, what signaling pathways are regulated by PRLs, and how to target PRLs in hematological malignancies. An improved understanding of how PRLs function and how they are regulated may facilitate the development of PRL inhibitors that are effective in cancer treatment.",
keywords = "hematological malignancy and therapeutic target, hematopoietic stem cell, oncogenic signaling, PRL, PTP4A, self-renewal",
author = "Michihiro Kobayashi and Sisi Chen and Rui Gao and Yunpeng Bai and Zhong-Yin Zhang and Yan Liu",
year = "2014",
doi = "10.4161/15384101.2014.954448",
language = "English (US)",
volume = "13",
pages = "2827--2835",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "18",

}

TY - JOUR

T1 - Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies

AU - Kobayashi, Michihiro

AU - Chen, Sisi

AU - Gao, Rui

AU - Bai, Yunpeng

AU - Zhang, Zhong-Yin

AU - Liu, Yan

PY - 2014

Y1 - 2014

N2 - The phosphatases of regenerating liver (PRLs), consisting PRL1, PRL2 and PRL3, are dual-specificity protein phosphatases that have been implicated as biomarkers and therapeutic targets in several solid tumors. However, their roles in hematological malignancies are largely unknown. Recent findings demonstrate that PRL2 is important for hematopoietic stem cell self-renewal and proliferation. In addition, both PRL2 and PRL3 are highly expressed in some hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Moreover, PRL deficiency impairs the proliferation and survival of leukemia cells through regulating oncogenic signaling pathways. While PRLs are potential novel therapeutic targets in hematological malignancies, their exact biological function and cellular substrates remain unclear. This review will discuss how PRLs regulate hematopoietic stem cell behavior, what signaling pathways are regulated by PRLs, and how to target PRLs in hematological malignancies. An improved understanding of how PRLs function and how they are regulated may facilitate the development of PRL inhibitors that are effective in cancer treatment.

AB - The phosphatases of regenerating liver (PRLs), consisting PRL1, PRL2 and PRL3, are dual-specificity protein phosphatases that have been implicated as biomarkers and therapeutic targets in several solid tumors. However, their roles in hematological malignancies are largely unknown. Recent findings demonstrate that PRL2 is important for hematopoietic stem cell self-renewal and proliferation. In addition, both PRL2 and PRL3 are highly expressed in some hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Moreover, PRL deficiency impairs the proliferation and survival of leukemia cells through regulating oncogenic signaling pathways. While PRLs are potential novel therapeutic targets in hematological malignancies, their exact biological function and cellular substrates remain unclear. This review will discuss how PRLs regulate hematopoietic stem cell behavior, what signaling pathways are regulated by PRLs, and how to target PRLs in hematological malignancies. An improved understanding of how PRLs function and how they are regulated may facilitate the development of PRL inhibitors that are effective in cancer treatment.

KW - hematological malignancy and therapeutic target

KW - hematopoietic stem cell

KW - oncogenic signaling

KW - PRL

KW - PTP4A

KW - self-renewal

UR - http://www.scopus.com/inward/record.url?scp=84964313604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964313604&partnerID=8YFLogxK

U2 - 10.4161/15384101.2014.954448

DO - 10.4161/15384101.2014.954448

M3 - Article

C2 - 25486470

AN - SCOPUS:84964313604

VL - 13

SP - 2827

EP - 2835

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 18

ER -